# Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment

> **NCT00288925** · PHASE1,PHASE2 · COMPLETED · sponsor: **Zeria Pharmaceutical** · enrollment: 30 (—)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Z-360

## Key facts

- **NCT ID:** NCT00288925
- **Lead sponsor:** Zeria Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2007-12
- **Final completion:** —
- **Target enrollment:** 30 (—)
- **Last updated:** 2009-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00288925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00288925, "Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00288925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*